CL2013003360A1 - “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct - Google Patents

“compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct

Info

Publication number: CL2013003360A1
Authority: CL; Chile
Prior art keywords: compounds; sulfonimidoyl; hyperproliferative; triazin; viruses
Prior art date: 2011-05-24

Application number

CL2013003360A

Other languages

English (en)

Inventor

Ulrich Lucking

Gerhard Siemeister

Dirk Kosemund

Philip Lienau

Rolf Bohlmann

Arne Scholz

Ulf Bomer

Gerd Ruthter

Mark Jean Gnoth

Carsten Schultz-Fademrecht

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-24

Filing date

2013-11-22

Publication date

2014-07-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003360(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-24 Priority claimed from EP11167317A external-priority patent/EP2527332A1/en

2013-11-22 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2014-07-04 Publication of CL2013003360A1 publication Critical patent/CL2013003360A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Cosmetics (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CL2013003360A 2011-05-24 2013-11-22 “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct CL2013003360A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11167317A EP2527332A1 (en)	2011-05-24	2011-05-24	4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
EP11180759		2011-09-09
EP12158030		2012-03-05

Publications (1)

Publication Number	Publication Date
CL2013003360A1 true CL2013003360A1 (es)	2014-07-04

Family

ID=46085997

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013003360A CL2013003360A1 (es)	2011-05-24	2013-11-22	“compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct

Country Status (42)

Country	Link
US (2)	US9669034B2 (es)
EP (1)	EP2714654B1 (es)
JP (1)	JP5955948B2 (es)
KR (1)	KR101958501B1 (es)
CN (1)	CN103702979B (es)
AP (1)	AP3884A (es)
AR (1)	AR086552A1 (es)
AU (1)	AU2012260983B2 (es)
BR (1)	BR112013029976A2 (es)
CA (1)	CA2837027C (es)
CL (1)	CL2013003360A1 (es)
CO (1)	CO6811860A2 (es)
CR (1)	CR20130620A (es)
CU (1)	CU24175B1 (es)
CY (1)	CY1116791T1 (es)
DK (1)	DK2714654T3 (es)
DO (1)	DOP2013000277A (es)
EA (1)	EA023418B1 (es)
EC (1)	ECSP13013040A (es)
ES (1)	ES2549529T3 (es)
GT (1)	GT201300293A (es)
HR (1)	HRP20151060T1 (es)
HU (1)	HUE027853T2 (es)
IL (1)	IL229314A (es)
JO (1)	JO3204B1 (es)
MA (1)	MA35132B1 (es)
ME (1)	ME02227B (es)
MX (1)	MX340803B (es)
MY (1)	MY165748A (es)
PE (1)	PE20141075A1 (es)
PH (1)	PH12013502411A1 (es)
PL (1)	PL2714654T3 (es)
PT (1)	PT2714654E (es)
RS (1)	RS54264B1 (es)
SG (2)	SG10201606952XA (es)
SI (1)	SI2714654T1 (es)
TN (1)	TN2013000485A1 (es)
TW (2)	TW201636330A (es)
UA (1)	UA112870C2 (es)
UY (1)	UY34095A (es)
WO (1)	WO2012160034A1 (es)
ZA (1)	ZA201309672B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2755394C (en)	2009-03-13	2021-10-19	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
KR101712035B1 (ko)	2009-06-29	2017-03-03	아지오스 파마슈티컬스 아이엔씨.	치료용 화합물 및 조성물
CA2793835C (en)	2009-10-21	2021-07-20	Agios Pharmaceuticals, Inc.	Methods and compositions for cell-proliferation-related disorders
CN108451955B (zh)	2011-05-03	2022-02-01	安吉奥斯医药品有限公司	用于治疗的丙酮酸激酶活化剂
TW201636330A (zh) *	2011-05-24	2016-10-16	拜耳知識產權公司	含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827170A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
CN102827073A (zh)	2011-06-17	2012-12-19	安吉奥斯医药品有限公司	治疗活性组合物和它们的使用方法
CA2848615C (en) *	2011-09-16	2020-02-25	Bayer Intellectual Property Gmbh	Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
AU2013207289B2 (en)	2012-01-06	2017-09-21	Les Laboratoires Servier	Therapeutically active compounds and their methods of use
US9474779B2 (en)	2012-01-19	2016-10-25	Agios Pharmaceuticals, Inc.	Therapeutically active compositions and their methods of use
NZ706999A (en)	2012-10-15	2018-12-21	Agios Pharmaceuticals Inc	Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
CN105492438B (zh) *	2013-07-04	2018-08-07	拜耳医药股份有限公司	磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
JP6529492B2 (ja)	2013-07-11	2019-06-12	アジオスファーマシューティカルズ，インコーポレイテッド	癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
KR102302091B1 (ko)	2013-07-11	2021-09-16	아지오스 파마슈티컬스 아이엔씨.	암 치료용의 ｉｄｈ２ 돌연변이체 억제제로서의 ｎ,６-비스(아릴 또는 헤테로아릴)-１，３，５-트리아진-２,４-디아민 화합물
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
WO2015003355A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
US20150031627A1 (en)	2013-07-25	2015-01-29	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
CN106232596A (zh) *	2014-03-13	2016-12-14	拜耳医药股份有限公司	含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物
AU2015229214B2 (en)	2014-03-14	2019-07-11	Les Laboratoires Servier	Pharmaceutical compositions of therapeutically active compounds
CA2973414A1 (en) *	2015-01-13	2016-07-21	Bayer Pharma Aktiengesellschaft	Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating leukemias
CA2980493A1 (en)	2015-03-24	2016-09-29	Bayer Pharma Aktiengesellschaft	Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma
US20180050040A1 (en)	2015-03-24	2018-02-22	Bayer Pharma Aktiengesellschaft	Use of 4-(4-fluoro-2-methoxyphenyl)-n--1,3,5-triazin-2-amine for treating lymphomas
WO2016150902A1 (en)	2015-03-24	2016-09-29	Bayer Pharma Aktiengesellschaft	Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers
LT3294740T (lt)	2015-05-08	2019-11-25	Hoffmann La Roche	Nauji sulfonimidoilpurinono junginiai ir dariniai virusinių infekcijų gydymui ir profilaktikai
EP4344703A1 (en)	2015-06-11	2024-04-03	Agios Pharmaceuticals, Inc.	Methods of using pyruvate kinase activators
MA43000B1 (fr)	2015-10-15	2021-11-30	Celgene Corp	Polythérapie pour le traitement de tumeurs malignes
MX390531B (es)	2015-10-15	2025-03-20	Servier Lab	Terapia de combinacion para tratar tumores malignos.
ES2834051T3 (es) *	2016-04-06	2021-06-16	Innovative Molecules Gmbh	Derivados de aminotiazol útiles como agentes antivirales
US10927086B2 (en)	2017-02-24	2021-02-23	Merck Sharp & Dohme Corp.	Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
AU2018344471B2 (en)	2017-10-05	2022-09-29	Innovative Molecules Gmbh	Enantiomers of substituted thiazoles as antiviral compounds
CA3090843A1 (en)	2018-02-13	2019-08-22	Bayer Aktiengesellschaft	Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-n-{4-[(s-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large b-cell lymphoma
US10980788B2 (en)	2018-06-08	2021-04-20	Agios Pharmaceuticals, Inc.	Therapy for treating malignancies
WO2020152629A1 (en)	2019-01-23	2020-07-30	Novartis Ag	New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
JPWO2021193982A1 (es) *	2020-03-27	2021-09-30
EP4174077A1 (en) *	2021-10-27	2023-05-03	Merck Patent GmbH	Electronic switching device

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1030660A (en)		1912-06-25	Henry C Hunt	Tool for removing floors, siding, scaffolds, &c.
GB1307271A (en)	1970-06-25	1973-02-14	Shell Int Research	Sulphoximine derivatives and their use in herbicidal compositions
MXPA02003436A (es)	1999-10-07	2002-08-20	Amgen Inc	Inhibidores de triazina cinasa.
KR100847169B1 (ko)	2000-12-21	2008-07-17	글락소 그룹 리미티드	혈관형성 조절제로서의 피리미딘아민
GB0103926D0 (en)	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
WO2003037346A1 (en)	2001-10-31	2003-05-08	Cell Therapeutics, Inc.	6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
ES2575522T3 (es)	2002-07-18	2016-06-29	Janssen Pharmaceutica Nv	Inhibidores de quinasas con triazina sustituida
DE10239042A1 (de)	2002-08-21	2004-03-04	Schering Ag	Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7407962B2 (en)	2003-02-07	2008-08-05	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds useful as inhibitors or protein kinases
US8084457B2 (en)	2003-09-15	2011-12-27	Lead Discovery Center Gmbh	Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
DE10349423A1 (de) *	2003-10-16	2005-06-16	Schering Ag	Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2008524191A (ja)	2004-12-17	2008-07-10	アストラゼネカアクチボラグ	Ｃｄｋ阻害剤としての４−（４−（イミダゾール−４−イル）ピリミジン−２−イルアミノ）ベンズアミド
WO2007023507A2 (en)	2005-06-20	2007-03-01	Wockhardt Limited	Oxazolidinones bearing antimicrobial activity composition and methods of preparation
DE102005062742A1 (de)	2005-12-22	2007-06-28	Bayer Schering Pharma Ag	Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
EP1803723A1 (de)	2006-01-03	2007-07-04	Bayer Schering Pharma Aktiengesellschaft	(2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs
TW201309635A (zh)	2006-02-10	2013-03-01	Dow Agrosciences Llc	殺蟲性之ｎ-取代（６-鹵烷基吡啶-３-基）烷基磺醯亞胺（二）
JP4305477B2 (ja)	2006-07-25	2009-07-29	トヨタ自動車株式会社	火花点火式内燃機関
DE102006041382A1 (de)	2006-08-29	2008-03-20	Bayer Schering Pharma Ag	Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
DE102006042143A1 (de)	2006-09-08	2008-03-27	Bayer Healthcare Aktiengesellschaft	Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en)	2006-11-15	2008-05-22	S*Bio Pte Ltd.	Indole sustituted pyrimidines and use thereof in the treatment of cancer
KR20090101905A (ko) *	2006-12-22	2009-09-29	노파르티스 아게	인돌-４-일-피리미디닐-일-아민 유도체 및 사이클린 의존성 키나제 억제제로서의 그의 용도
US20100048597A1 (en) *	2006-12-22	2010-02-25	Novartis Ag	Organic Compounds and Their Uses
US8486941B2 (en)	2007-03-12	2013-07-16	Ym Biosciences Australia Pty Ltd	Phenyl amino pyrimidine compounds and uses thereof
US8436007B2 (en)	2007-04-24	2013-05-07	Ingenium Pharmaceuticals Gmbh	Inhibitors of protein kinases
JP5566880B2 (ja)	2007-04-24	2014-08-06	インゲニウムファーマシューティカルズジーエムビーエイチ	プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
JP5379787B2 (ja)	2007-04-24	2013-12-25	インゲニウムファーマシューティカルズジーエムビーエイチ	プロテインキナーゼの阻害剤
WO2008132138A1 (en)	2007-04-25	2008-11-06	Ingenium Pharmaceuticals Gmbh	Derivatives of 4,6-disubstituted aminopyrimidines
AU2008279513B2 (en)	2007-07-20	2013-09-26	Dow Agrosciences Llc	Increasing plant vigor
CA2698511C (en)	2007-09-04	2016-10-11	The Scripps Research Institute	Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2009029998A1 (en)	2007-09-06	2009-03-12	Cytopia Research Pty Ltd	Retrometabolic compounds
GB0805477D0 (en) *	2008-03-26	2008-04-30	Univ Nottingham	Pyrimidines triazines and their use as pharmaceutical agents
WO2010009155A2 (en)	2008-07-14	2010-01-21	Gilead Colorado, Inc.	Fused heterocyclyc inhibitor compounds
EP2179991A1 (de) *	2008-10-21	2010-04-28	Bayer Schering Pharma Aktiengesellschaft	Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US8415381B2 (en) *	2009-07-30	2013-04-09	Novartis Ag	Heteroaryl compounds and their uses
CN102791697A (zh)	2009-10-12	2012-11-21	瑞科西有限公司	作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
KR101752519B1 (ko)	2010-03-22	2017-06-29	리드 디스커버리 센터 게엠베하	제약 활성 이치환된 트리아진 유도체
EP2680852A1 (en)	2011-03-02	2014-01-08	Lead Discovery Center GmbH	Pharmaceutically active disubstituted triazine derivatives
US9242937B2 (en)	2011-03-02	2016-01-26	Bayer Intellectual Property Gmbh	Pharmaceutically active disubstituted pyridine derivatives
EP2699554B1 (en) *	2011-04-19	2016-11-02	Bayer Intellectual Property GmbH	Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines
TW201636330A (zh) *	2011-05-24	2016-10-16	拜耳知識產權公司	含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
EP2527332A1 (en)	2011-05-24	2012-11-28	Bayer Intellectual Property GmbH	4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
US9108926B2 (en)	2011-09-16	2015-08-18	Bayer Intellectual Property Gmbh	Disubstituted 5-fluoro-pyrimidines
CA2848615C (en)	2011-09-16	2020-02-25	Bayer Intellectual Property Gmbh	Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
CA2888371C (en)	2012-10-18	2021-06-08	Ulrich Lucking	5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group
CN105283453B (zh)	2012-10-18	2018-06-22	拜耳药业股份公司	含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物
ES2597232T3 (es)	2012-10-18	2017-01-17	Bayer Pharma Aktiengesellschaft	4-(orto)-fluorofenil-5-fluoropirimidin-2-il aminas que contienen un grupo sulfona
JP6263193B2 (ja)	2012-11-15	2018-01-17	バイエルファーマアクチエンゲゼルシャフト	スルホキシイミン基を含んでいる５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体
US9499492B2 (en)	2012-11-15	2016-11-22	Bayer Pharma Aktiengesellschaft	4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group
TW201418243A (zh)	2012-11-15	2014-05-16	Bayer Pharma AG	含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物
CN105492438B (zh)	2013-07-04	2018-08-07	拜耳医药股份有限公司	磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途
CN106232596A (zh)	2014-03-13	2016-12-14	拜耳医药股份有限公司	含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物

2012
- 2012-05-18 TW TW105122136A patent/TW201636330A/zh unknown
- 2012-05-18 TW TW101117904A patent/TWI555737B/zh not_active IP Right Cessation
- 2012-05-21 PE PE2013002560A patent/PE20141075A1/es not_active Application Discontinuation
- 2012-05-21 US US14/122,063 patent/US9669034B2/en not_active Expired - Fee Related
- 2012-05-21 PH PH1/2013/502411A patent/PH12013502411A1/en unknown
- 2012-05-21 EP EP12721558.0A patent/EP2714654B1/en active Active
- 2012-05-21 CA CA2837027A patent/CA2837027C/en active Active
- 2012-05-21 PT PT127215580T patent/PT2714654E/pt unknown
- 2012-05-21 RS RS20150640A patent/RS54264B1/sr unknown
- 2012-05-21 AP AP2013007254A patent/AP3884A/en active
- 2012-05-21 AU AU2012260983A patent/AU2012260983B2/en not_active Ceased
- 2012-05-21 EA EA201301320A patent/EA023418B1/ru not_active IP Right Cessation
- 2012-05-21 SG SG10201606952XA patent/SG10201606952XA/en unknown
- 2012-05-21 MY MYPI2013702220A patent/MY165748A/en unknown
- 2012-05-21 JP JP2014511836A patent/JP5955948B2/ja not_active Expired - Fee Related
- 2012-05-21 ME MEP-2015-168A patent/ME02227B/me unknown
- 2012-05-21 ES ES12721558.0T patent/ES2549529T3/es active Active
- 2012-05-21 CN CN201280036561.6A patent/CN103702979B/zh active Active
- 2012-05-21 SG SG2013082870A patent/SG194856A1/en unknown
- 2012-05-21 UA UAA201314969A patent/UA112870C2/uk unknown
- 2012-05-21 BR BR112013029976A patent/BR112013029976A2/pt not_active Application Discontinuation
- 2012-05-21 CU CUP2013000157A patent/CU24175B1/es active IP Right Grant
- 2012-05-21 HR HRP20151060TT patent/HRP20151060T1/hr unknown
- 2012-05-21 PL PL12721558T patent/PL2714654T3/pl unknown
- 2012-05-21 DK DK12721558.0T patent/DK2714654T3/en active
- 2012-05-21 KR KR1020137033871A patent/KR101958501B1/ko not_active Expired - Fee Related
- 2012-05-21 SI SI201230330T patent/SI2714654T1/sl unknown
- 2012-05-21 MX MX2013013711A patent/MX340803B/es active IP Right Grant
- 2012-05-21 WO PCT/EP2012/059399 patent/WO2012160034A1/en not_active Ceased
- 2012-05-21 HU HUE12721558A patent/HUE027853T2/en unknown
- 2012-05-23 JO JOP/2012/0122A patent/JO3204B1/ar active
- 2012-05-24 UY UY0001034095A patent/UY34095A/es not_active Application Discontinuation
- 2012-05-24 AR ARP120101840A patent/AR086552A1/es not_active Application Discontinuation
2013
- 2013-11-07 IL IL229314A patent/IL229314A/en active IP Right Grant
- 2013-11-22 CO CO13275593A patent/CO6811860A2/es active IP Right Grant
- 2013-11-22 EC ECSP13013040 patent/ECSP13013040A/es unknown
- 2013-11-22 GT GT201300293A patent/GT201300293A/es unknown
- 2013-11-22 CL CL2013003360A patent/CL2013003360A1/es unknown
- 2013-11-22 DO DO2013000277A patent/DOP2013000277A/es unknown
- 2013-11-22 MA MA36460A patent/MA35132B1/fr unknown
- 2013-11-22 TN TNP2013000485A patent/TN2013000485A1/fr unknown
- 2013-11-25 CR CR20130620A patent/CR20130620A/es unknown
- 2013-12-20 ZA ZA2013/09672A patent/ZA201309672B/en unknown
2015
- 2015-10-08 CY CY20151100912T patent/CY1116791T1/el unknown
2017
- 2017-04-14 US US15/488,155 patent/US9962389B2/en active Active

Also Published As

Publication number	Publication date
US20170217949A1 (en)	2017-08-03
IL229314A (en)	2017-01-31
CR20130620A (es)	2014-02-04
JP2014515363A (ja)	2014-06-30
CN103702979A (zh)	2014-04-02
ES2549529T3 (es)	2015-10-29
US20140315906A1 (en)	2014-10-23
SI2714654T1 (sl)	2015-11-30
UA112870C2 (uk)	2016-11-10
CN103702979B (zh)	2016-09-28
EA023418B1 (ru)	2016-06-30
TN2013000485A1 (en)	2015-03-30
HUE027853T2 (en)	2016-11-28
IL229314A0 (en)	2014-01-30
AR086552A1 (es)	2014-01-08
ME02227B (me)	2016-02-20
ECSP13013040A (es)	2014-01-31
US9669034B2 (en)	2017-06-06
MX340803B (es)	2016-07-27
WO2012160034A1 (en)	2012-11-29
NZ617628A (en)	2014-12-24
KR101958501B1 (ko)	2019-03-14
PH12013502411A1 (en)	2022-04-08
GT201300293A (es)	2015-01-16
CA2837027A1 (en)	2012-11-29
JP5955948B2 (ja)	2016-07-20
EP2714654B1 (en)	2015-07-22
AU2012260983A1 (en)	2013-11-28
PL2714654T3 (pl)	2015-12-31
BR112013029976A2 (pt)	2017-01-31
EP2714654A1 (en)	2014-04-09
SG194856A1 (en)	2013-12-30
DOP2013000277A (es)	2014-04-15
AP3884A (en)	2016-11-05
EA201301320A1 (ru)	2014-05-30
TW201636330A (zh)	2016-10-16
CY1116791T1 (el)	2017-03-15
SG10201606952XA (en)	2016-10-28
UY34095A (es)	2013-01-03
TWI555737B (zh)	2016-11-01
KR20140041571A (ko)	2014-04-04
AU2012260983B2 (en)	2016-08-25
RS54264B1 (sr)	2016-02-29
HRP20151060T1 (hr)	2015-11-06
PT2714654E (pt)	2015-10-29
AP2013007254A0 (en)	2013-11-30
MY165748A (en)	2018-04-23
MX2013013711A (es)	2014-02-27
MA35132B1 (fr)	2014-05-02
DK2714654T3 (en)	2015-10-26
TW201249817A (en)	2012-12-16
US9962389B2 (en)	2018-05-08
PE20141075A1 (es)	2014-09-06
CU24175B1 (es)	2016-04-25
JO3204B1 (ar)	2018-03-08
CU20130157A7 (es)	2014-03-26
ZA201309672B (en)	2022-03-30
CO6811860A2 (es)	2013-12-16
CA2837027C (en)	2020-04-14

Publication	Publication Date	Title
CL2013003360A1 (es)	2014-07-04	“compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
CL2013001141A1 (es)	2013-10-04	Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2012001176A1 (es)	2012-08-31	Compuestos derivados de bencimidazol-imidazol, inhibidores del virus de la hepatitis c (hcv); composición farmacéutica que los comprende; combinación farmacéutica; uso en la prevención o tratamiento de infección de hcv.
CL2013000727A1 (es)	2013-08-23	Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
CL2014003634A1 (es)	2015-11-06	Inhibidores del virus de la hepatitis c
CL2012001959A1 (es)	2012-12-07	Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2011002830A1 (es)	2012-03-23	Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CL2015000295A1 (es)	2015-04-24	Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2012002489A1 (es)	2012-11-30	Compuestos derivados de sililo nafto-imidazol; composición farmacéutica; y su uso para prevenir o tratar una infección por el virus de la hepatitis c.
MX387352B (es)	2025-03-18	Nuevos inhibidores de replicación viral.
BR112014030639A2 (pt)	2017-06-27	inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt)	2017-06-27	inibidores macrocíclicos de vírus flaviviridae
CL2013002939A1 (es)	2014-07-04	Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
CL2015000487A1 (es)	2015-06-12	Compuestos derivados de sulfamoilarilamidas; composicion farmaceutica que los comprende, util para la prevencion o tratamiento de una infeccion por el virus de la hepatitis b (vhb).
CR20150085A (es)	2015-04-06	Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
CL2014002093A1 (es)	2014-11-21	Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2013001339A1 (es)	2014-03-07	Compuestos derivados heterociclicos condensados, con actividad antiviral; composicion farmaceutica que los comprende; y su uso para la prevencion o tratamiento de la infeccion de vih.
EA201491548A1 (ru)	2015-02-27	2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CL2011001224A1 (es)	2011-09-16	Compuestos derivados de benzofurano-3-carboxamida; composicion farmaceutica que los comprende; y su uso en tratamiento del virus de la hepatitis c.
CL2014000311A1 (es)	2014-10-17	Compuestos derivados de benzotiazepinas sustituidas; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis de la infeccion del virus sincicial respiratorio.
EA200970916A1 (ru)	2010-04-30	Соединения 5,6-дигидро-1н-пиридин-2-она
CL2013003229A1 (es)	2014-09-05	Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
PH12015502230A1 (en)	2016-02-01	Novel viral replication inhibitors
PH12014500385A1 (en)	2020-06-22	Benzofuran compounds for the treatment of hepatitis c virus infections
CL2013002971A1 (es)	2014-06-13	Compuestos derivados de 5-(fenil/piridinil-etinil)-2-piridina/2-pirimidina-carboxamida, moduladores mglur5; composición farmacéutica que los comprende; proceso de preparación de ellos; y su uso en el tratamiento de esquizofrenia o enfermedades cognitivas.